Darla Liles is an Oncology physician affiliated with East Carolina University. OpenAlex indexes 146 publications with 2,591 citations (h-index 21).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Celgene CorporationProgram year20251 payment
- Legend Biotech USA Inc.Program year20251 payment
- Masimo CorporationProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
43.2%Opioid Agonist32.4%Oxycodone Hcl55%Morphine Sulfate Er16%Oxycontin12%Oxycodone-Acetaminophen6%Hydromorphone Hcl5%Tramadol Hcl3%Morphine Sulfate2%Hydromorphone Er2%Part D<11 patientsGabapentinoids3%Gabapentin51%Pregabalin49%Part D<11 patients+ 6 more classes in this area
Cancer & immunology
28.1%Thalidomide Analog8.6%Revlimid84%Pomalyst16%Part D<11 patientsAntimetabolite7.9%Hydroxyurea100%Part D≥38 patients+ 5 more classes in this area
Metabolism & gastrointestinal
8%Potassium supplement2.6%Potassium Chloride100%Part D≥13 patientsSerotonin-3 Receptor Antagonist2.2%Ondansetron Odt62%Ondansetron Hcl38%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 1993–2002 per NIH RePORTER. The latest:
- HIV-1 PATIENTS WITH HEMOPHILIA A OR B
University of North Carolina Chapel Hill
FY2002$190,747M01RR000046 - HIV-1 PATIENTS WITH HEMOPHILIA A OR B
University of North Carolina Chapel Hill
FY2001$294,555M01RR000046 - HIV-1 PATIENTS WITH HEMOPHILIA A OR B
University of North Carolina Chapel Hill
FY2001$190,747M01RR000046
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Blase Carabello
East Carolina University
Robert Fanelli, MD
East Carolina University
Hans Tillmann, MD
East Carolina University
Walter Chitwood, MD
East Carolina University
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”